
Sign up to save your podcasts
Or
The first half of 2025 was decidedly mixed for many publicly traded healthcare companies, and they’re facing murky waters in the back half of the year amid policy and cost upheaval.
In this episode of "Podnosis," Fierce Healthcare Associate Editor Dave Muoio and Senior Writer Paige Minemyer break down the topline takeaways from another round of corporate earnings calls, including a look at executive commentary on the “big, beautiful” policy environment.
To learn more about the topics in this episode:
See omnystudio.com/listener for privacy information.
4.7
33 ratings
The first half of 2025 was decidedly mixed for many publicly traded healthcare companies, and they’re facing murky waters in the back half of the year amid policy and cost upheaval.
In this episode of "Podnosis," Fierce Healthcare Associate Editor Dave Muoio and Senior Writer Paige Minemyer break down the topline takeaways from another round of corporate earnings calls, including a look at executive commentary on the “big, beautiful” policy environment.
To learn more about the topics in this episode:
See omnystudio.com/listener for privacy information.
4,322 Listeners
1,066 Listeners
4,169 Listeners
30,228 Listeners
2,289 Listeners
339 Listeners
56,020 Listeners
224 Listeners
477 Listeners
9,515 Listeners
317 Listeners
185 Listeners
391 Listeners
512 Listeners
163 Listeners